Literature DB >> 32845153

Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.

Stefano Federico1, Luca Pozzetti1, Alessandro Papa1, Gabriele Carullo1, Sandra Gemma1, Stefania Butini1, Giuseppe Campiani1, Nicola Relitti1.   

Abstract

Toll-like receptors (TLRs) are a class of proteins that recognize pathogen-associated molecular patterns (PAMPs) and damaged-associated molecular patterns (DAMPs), and they are involved in the regulation of innate immune system. These transmembrane receptors, localized at the cellular or endosomal membrane, trigger inflammatory processes through either myeloid differentiation primary response 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling pathways. In the last decades, extensive research has been performed on TLR modulators and their therapeutic implication under several pathological conditions, spanning from infections to cancer, from metabolic disorders to neurodegeneration and autoimmune diseases. This Perspective will highlight the recent discoveries in this field, emphasizing the role of TLRs in different diseases and the therapeutic effect of their natural and synthetic modulators, and it will discuss insights for the future exploitation of TLR modulators in human health.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32845153     DOI: 10.1021/acs.jmedchem.0c01049

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response.

Authors:  Ming-Hsiu Yang; Jamie L Russell; Yuto Mifune; Ying Wang; Hexin Shi; Eva Marie Y Moresco; Daniel J Siegwart; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2022-06-29       Impact factor: 8.039

Review 2.  Therapeutic applications of toll-like receptors (TLRs) agonists in AML.

Authors:  Ye Peng; Yanzhong Wang; Manling Wang; Jianping Lan; Yirui Chen
Journal:  Clin Transl Oncol       Date:  2022-08-13       Impact factor: 3.340

3.  Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-07-21       Impact factor: 4.632

4.  Synthesis, structure-activity relationship studies and evaluation of a TLR 3/8/9 agonist and its analogues.

Authors:  Anindya Sarkar; Anushka C Galasiti Kankanamalage; Qian Zhang; Heng Cheng; Prasanna Sivaprakasam; Joseph Naglich; Chunshan Xie; Sanjeev Gangwar; Dale L Boger
Journal:  Med Chem Res       Date:  2021-05-18       Impact factor: 2.351

5.  Spiro(isobenzofuranazetidine) Compounds for Treating Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-08-17       Impact factor: 4.632

6.  Novel Hexahydro-1H-Pyrazino[1,2-a]pyrazine Compounds for Treating Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2020-12-11       Impact factor: 4.345

Review 7.  Medicinal Plants and Isolated Molecules Demonstrating Immunomodulation Activity as Potential Alternative Therapies for Viral Diseases Including COVID-19.

Authors:  Hassan A Alhazmi; Asim Najmi; Sadique A Javed; Shahnaz Sultana; Mohammed Al Bratty; Hafiz A Makeen; Abdulkarim M Meraya; Waquar Ahsan; Syam Mohan; Manal M E Taha; Asaad Khalid
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 8.  Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders.

Authors:  Silke Miller; Maria-Jesus Blanco
Journal:  RSC Med Chem       Date:  2021-04-13

Review 9.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

Review 10.  Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.

Authors:  Saghar Pahlavanneshan; Ali Sayadmanesh; Hamidreza Ebrahimiyan; Mohsen Basiri
Journal:  J Immunol Res       Date:  2021-05-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.